Operator fluency on fresh ground

Ionis Pharmaceuticals, Inc. (IONS) — this company's answers

The model's full reasoning — Q1 2017 call → NOWe need to answer YES or NO based on the transcript. The question asks: On this call, when analysts probe a RECENTLY EMERGED positive element of the business — something whose meaningful contribution began only within roughly the last few quarters — does management respond with UNHESITATING, GRANULAR OPERATIONAL COMMAND: answering follow-up questions about that new element with specific, present-tense working detail... while conveying that the element's contribution to the reported results is still early? We need to identify if such a dynamic occurs. The transcript includes Q&A. Analysts ask questions. The recently emerged positive element could be SPINRAZA launch, or volanesorsen, or IONIS-TTRRx, etc. But we need to see if management gives granular operational detail in response to follow-up questions, and conveys that it's still early. Let's examine the Q&A: First question from Eric Schmidt about SPINRAZA: "Maybe on SPINRAZA. I know that Lynne mentioned that patients can get broader access if they have Type 2 or 3 disease. But in the weeks since the CHERISH data were presented at AAN, have you seen any payers change their blanket policy coverages?" Lynne responds: "Eric, there have been some. It's probably a better question to ask -- because these things, obviously, are changing on a day-to-day basis, it's probably a better question to ask Biogen. But Biogen is making all those data available to payers and we do expect that to be a successful offer." That is not granular operational detail; it defers to Biogen, and is general. Then Eric asks a science question about CAG repeats and Huntington's. Stan answers with a general statement about confidence, not operational detail. Next question from Yale Jen about NURTURE study and presymptomatic patients. He asks whether they will start to see patients seeking treatment and reimbursement landscape. Stan says: "We certainly do think that it's appropriate to treat SMA patients as early as possible. And we would expect, given the data, that others, including payers, would agree I think for the specifics of what's going on right now. I would recommend that you ask Biogen more details." Again, defers, no granular detail. Then Yale asks about volanesorsen Phase III for FPL.

← Back to the full IONS analysis